



**HAL**  
open science

## Influence of $\beta$ -adrenoceptor gene polymorphisms on $\beta$ -adrenoceptor expression in human lung

Linda J. Kay, S Kim Suvarna, Anne-Marie Scola, Amin Rostami-Hodjegan,  
Russell Chess-Williams, Peter T. Peachell

► **To cite this version:**

Linda J. Kay, S Kim Suvarna, Anne-Marie Scola, Amin Rostami-Hodjegan, Russell Chess-Williams, et al.. Influence of  $\beta$ -adrenoceptor gene polymorphisms on  $\beta$ -adrenoceptor expression in human lung. *Pulmonary Pharmacology & Therapeutics*, 2010, 23 (2), pp.71. 10.1016/j.pupt.2009.10.013 . hal-00614332

**HAL Id: hal-00614332**


**<https://hal.science/hal-00614332>**

Submitted on 11 Aug 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Accepted Manuscript



Title: Influence of  $\beta_2$ -adrenoceptor gene polymorphisms on  $\beta_2$ -adrenoceptor expression in human lung

Authors: Linda J. Kay, S Kim Suvarna, Anne-Marie Scola, Amin Rostami-Hodjegan, Russell Chess-Williams, Peter T. Peachell

PII: S1094-5539(09)00127-8

DOI: [10.1016/j.pupt.2009.10.013](https://doi.org/10.1016/j.pupt.2009.10.013)

Reference: YPUPT 968

To appear in: *Pulmonary Pharmacology & Therapeutics*

Received Date: 6 March 2009

Revised Date: 13October2009

Accepted Date: 26 October 2009

Please cite this article as: Kay LJ, Suvarna K, Scola A-M, Rostami-Hodjegan A, Chess-Williams R, Peachell PT. Influence of  $\beta_2$ -adrenoceptor gene polymorphisms on  $\beta_2$ -adrenoceptor expression in human lung, *Pulmonary Pharmacology & Therapeutics* (2009), doi: [10.1016/j.pupt.2009.10.013](https://doi.org/10.1016/j.pupt.2009.10.013)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## **Influence of $\beta_2$ -adrenoceptor gene polymorphisms on $\beta_2$ -adrenoceptor expression in human lung**

Linda J Kay<sup>a</sup>, S Kim Suvarna<sup>b</sup>, Anne-Marie Scola<sup>a</sup>, Amin Rostami-Hodjegan<sup>a</sup>, Russell Chess-Williams<sup>c</sup> and Peter T Peachell<sup>a</sup>

<sup>a</sup>Academic Unit of Respiratory Medicine, University of Sheffield, The Medical School (Floor M), Beech Hill Road, Sheffield S10 2RX, UK

<sup>b</sup>Department of Histopathology, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK

<sup>c</sup>Faculty of Health Sciences and Medicine, Bond University, Queensland 4229, Australia

**Running Title;** lung  $\beta_2$ -adrenoceptors

**Author for correspondence:**

Peter Peachell

email; [p.t.peachell@shef.ac.uk](mailto:p.t.peachell@shef.ac.uk)

telephone; +44-114-271-2063

fax; +44-114-271-1863

## Abstract

**Background:** The aim of the present study was to establish whether polymorphisms, especially those within the promoter region, of the  $\beta_2$ -adrenoceptor gene (*ADRB2*) influence  $\beta_2$ -adrenoceptor expression in human lung.

**Methods:** The density of  $\beta$ -adrenoceptors in human lung tissue (n=88) was determined by saturation binding using the radioligand, iodinated cyanopindolol. Discrimination of  $\beta_1$ - and  $\beta_2$ -adrenoceptors was determined using the highly selective  $\beta_1$ -adrenoceptor antagonist, CGP20712A. Genotype was determined at 5 positions of *ADRB2* previously reported as polymorphic. Potential influences of single nucleotide polymorphisms (SNPs) within the promoter region (-367, -47) and coding block (46, 79, 491) of *ADRB2* on  $\beta_2$ -adrenoceptor expression were investigated.

**Results:** The density of  $\beta_2$ -adrenoceptors was variable among the 88 lung preparations studied ranging from 17 to 177 fmol/mg protein (mean $\pm$ S.E.M., 72 $\pm$ 4 fmol/mg protein). There was no influence of genotype on  $\beta_2$ -adrenoceptor expression for any of the polymorphisms studied except at position 491. The polymorphism at position 491C>T, leading to a change from thr to ile at amino acid 164, is uncommon. Preparations genotyped as heterozygous (126 $\pm$ 15 fmol/mg protein; n=5) expressed significantly ( $P = 0.0005$ ) higher levels of  $\beta_2$ -adrenoceptor than those that were homozygous (69 $\pm$ 4 fmol/mg protein; n=83).

**Conclusion:** With the exception of position 491, these data indicate that polymorphisms of *ADRB2* do not influence  $\beta_2$ -adrenoceptor expression in human lung.

**Key words:** asthma; human lung; *ADRB2*;  $\beta_2$ -adrenoceptor; SNP

**Abbreviations:**

*ADRB2*,  $\beta_2$ -adrenoceptor gene

BUP, beta upstream peptide

dNTP, deoxynucleotide triphosphate

PCR, polymerase chain reaction

RFLP, restriction fragment length polymorphism

SNP, single nucleotide polymorphism

## 1. Introduction

A large number of studies has shown that the gene for the  $\beta_2$ -adrenoceptor (*ADRB2*) is polymorphic [1]. Single nucleotide polymorphisms (SNPs) have now been found not only within the promoter region and the coding block [1] but also within the 3' untranslated region [2] of *ADRB2*. Additional studies have demonstrated that some of these polymorphisms may influence both receptor function and expression [1,3,4]. This could, potentially, impact quite heavily on how effectively agonists activate  $\beta_2$ -adrenoceptors. This is of particular interest in the context of asthma therapy since  $\beta_2$ -adrenoceptor agonists are the most commonly prescribed drugs used to treat asthma [5]. Consequently, a considerable body of work has emerged geared toward establishing whether polymorphisms in *ADRB2* influence the therapeutic benefits of  $\beta_2$ -adrenoceptor agonists in asthma [6].

$\beta_2$ -adrenoceptor agonists act in asthma primarily as bronchodilators relaxing airway smooth muscle but additional effects could include the stabilization of pulmonary cell activity [7,8]. One factor that could influence the effectiveness of  $\beta_2$ -adrenoceptor agonists in the treatment of asthma is the extent of receptor expression in the lung. Receptor density is known to influence both the potency and efficacy of agonists [9]. This may be of especial importance in asthma since many of the  $\beta$ -adrenoceptor agonists used clinically, such as salbutamol and salmeterol, are partial agonists [10]. Partial agonists are unable to attain maximal responses despite full receptor occupancy and responses are particularly dependent on the size of the functional receptor population [9]. Should receptor expression be compromised, the response to a partial agonist will be further attenuated whereas a full agonist may continue to evoke maximal responses.

Polymorphisms within the promoter region of *ADRB2* have been associated with the regulation of receptor expression [11-15]. In particular, a polymorphism at position –47 has been strongly linked to  $\beta_2$ -adrenoceptor expression [11]. Position –47 is found within an open-reading frame, just upstream of the start site for the  $\beta_2$ -adrenoceptor, that encodes a putative 19 amino acid peptide that is sometimes referred to as beta upstream peptide (BUP) [16]. The polymorphism (-47T>C) leads to a change in the terminal residue of BUP from cys to arg. BUP-arg has been reported to attenuate  $\beta_2$ -adrenoceptor expression [11]. In addition to position –47, position –367 within the promoter region has also been linked to influencing receptor expression as the polymorphism (-367T>C) interrupts a potential binding site for transcription factors [12,14].

An influence of polymorphisms on  $\beta_2$ -adrenoceptor expression has been assessed in transfected cells and lymphocytes with equivocal outcomes [11-15,17]. The aim of the present study was to perform a comprehensive analysis of the influence of polymorphisms across *ADRB2* on  $\beta_2$ -adrenoceptor expression in human lung tissue.

## 2. Materials and Methods

### 2.1. Buffers

Tris buffer contained (mM): Tris 50, NaCl 154, MgCl<sub>2</sub>.6H<sub>2</sub>O 10, EDTA 2. The pH of Tris buffer was titrated to 7.4.

### 2.2. Preparation of compounds

CGP20712A (2-hydroxy-5-(2-(hydroxy-3-(4((1-methyl-4-trifluoromethyl)-1-H-imidazol-2-yl)-phenoxy)-propyl)-aminoethoxy)-benzamide) and (±)-propranolol HCl, were prepared daily as stock solutions (10 mM) in Tris buffer.

### 2.3. Lung tissue

Human lung tissue was obtained, anonymized, from surgical resections of patients with the approval of the Local Research Ethics Committee. Most of the patients were undergoing surgery for carcinoma. The majority of the patients were Caucasian (90%), and most were male (70%).

### 2.4. Radioligand binding

Membrane fractions were prepared from lung tissue by methods that have been described previously [18,19]. The tissue (100 - 150 mg) was homogenised in ice-cold Tris buffer using an Ultra Turrax homogeniser for 20 s followed by four strokes (x4) of a Teflon homogeniser. The homogenate was centrifuged (500 g, 10 min) and the supernatant was harvested and subjected to further centrifugation (40,000 g, 15 min) in an ultra-centrifuge (L80, Beckman). The pellet was washed and the high-speed centrifugation step repeated.



The pellet was resuspended in Tris buffer and used in receptor binding assays. All procedures were carried out at 4 °C.

In saturation binding assays, the membrane preparations were assayed for  $\beta$ -adrenoceptor binding sites using [ $^{125}$ I]-cyanopindolol. Membrane suspensions (100  $\mu$ l) were incubated (1 h, 37 °C) using a range of radioligand concentrations (0.01563 - 2 nM) in a total volume of 250  $\mu$ l. Non-specific binding was determined by displacement with propranolol (1  $\mu$ M). Specific binding, expressed as a percentage of the total binding, was  $87 \pm 1\%$  at a [ $^{125}$ I]-cyanopindolol concentration of 0.0625 nM. The subtypes of  $\beta$ -adrenoceptor present in membranes were determined in competition studies with the use of the highly selective  $\beta_1$ -adrenoceptor antagonist, CGP20712A [20]. Membrane preparations (100  $\mu$ l) were incubated (1 h, 37 °C) with CGP20712A ( $10^{-14}$  –  $10^{-4}$  M) in the presence of [ $^{125}$ I]-cyanopindolol (0.0625 nM) in a total volume of 250  $\mu$ l. Although full displacement curves using an extensive range of CGP20712A concentrations were performed for some preparations (n=23), further studies indicated that the use of a single concentration (10 nM) of the antagonist was sufficiently discriminatory to determine the split of  $\beta$ -adrenoceptors present in lung membranes and this approach was used in the majority of instances.

Additions of ice-cold Tris buffer were used to terminate the reactions followed by rapid filtration through Whatman GF/B glass fibre filters. The filters were rapidly washed four times with 3 ml ice-cold buffer and the radioactivity remaining on filters measured in a Packard Cobra auto-gamma counter. All saturation binding experiments were performed in duplicate. All competition binding experiments were performed either in duplicate or quadruplicate. Twenty-five of the 88 lung preparations that were studied in

these binding experiments were repeat assayed to ensure data reproducibility. These were, primarily, preparations that were at either end of the population's spectrum such as preparations that expressed very high or very low levels of  $\beta$ -adrenoceptors. Protein content of the membranes was determined by the method of Lowry et al [21].

### 2.5. Genotyping

For genotypic analyses of the  $\beta_2$ -adrenoceptor, genomic DNA was extracted from a small quantity of human lung tissue using a modification of the chloroform extraction and ethanol precipitation method described elsewhere [22]. The extracted DNA was amplified, using primers specific for *ADRB2* (see Table 1), by polymerase chain reaction (PCR). The reaction constituents for PCR were, genomic DNA (70 - 100 ng), dNTPs (200  $\mu$ M of each),  $MgSO_4$  (1 or 1.4 mM), Tris- $SO_4$  (pH 9.1; 60 mM),  $(NH_4)_2SO_4$  (18 mM), both primers (1  $\mu$ M of each) and ELONGASE enzyme mix (1  $\mu$ l) in a final volume of 50  $\mu$ l. Conditions were essentially as described previously and involved 35 cycles of PCR [23]. All PCR products were visualised with ethidium bromide staining on agarose gels.

PCR products were then subjected to genotypic analysis by either automated sequencing or restriction fragment length polymorphism (RFLP). PCR products generated from primer pair 1 (see Table 1) permitted determination of polymorphisms at nucleotide position -367 whereas products generated from primer pair 2 allowed determinations at positions -47, 46 and 79. PCR products subjected to automated sequencing (products of primer pairs 1 and 2) were first purified by either ethanol precipitation or using a QIAquick PCR purification kit before sequencing (Applied

Biosystems, 373 Stretch). Alternatively, in order to determine the genotype at position 491, RFLP was performed on PCR products generated by primer pair 3 (Table 1) using the restriction enzyme *MnII* according to methods similar to those described elsewhere [24]. In order to confirm the genotypes determined by RFLP for position 491, all heterozygotes (n=5) and a random sample of homozygotes (n=9) were also genotyped by automated sequencing.

### 2.6. Materials

Materials were purchased from the following sources: QIAquick (Qiagen, Sussex, UK), Tris (Calbiochem, Nottingham, UK); propranolol (Sigma, Poole, UK); [<sup>125</sup>I]-cyanopindolol (New England Nuclear, Stevenage, UK); agarose, ELONGASE enzyme mix (Invitrogen, Paisley, UK); dNTPs (Promega, Southampton, UK); *MnII* (New England Biolabs, Hitchin, UK). CGP20712A was kindly supplied as a gift from Ciba-Geigy (Basel, Switzerland).

### 2.7. Data analysis

Receptor densities ( $B_{\max}$ ) and radioligand affinity ( $K_D$ ) were determined by non-linear regression analysis of saturation curves (GraphPad Prism, version 4). To determine whether  $\beta$ -adrenoceptor density varies among lung regions, repeated measures ANOVA was performed. To determine whether genotype influences  $\beta$ -adrenoceptor density either Kruskal-Wallis or Mann-Whitney tests were performed (Graph Pad InStat, version 4). Hardy-Weinberg equilibrium was determined by means of  $\chi^2$  goodness-of-fit tests.

### 3. Results

#### 3.1. $\beta$ -adrenoceptor expression in human lung

The density of  $\beta$ -adrenoceptors in membranes generated from lung tissue was determined by saturation binding using the radioligand [ $^{125}$ I]-cyanopindolol (0.01563 – 2 nM). The total  $\beta$ -adrenoceptor density was variable among the 88 lung preparations studied ranging from 19 to 180 fmol/mg protein (mean $\pm$ S.E.M., 80 $\pm$ 4 fmol/mg protein). Representative saturation binding data are provided (Fig. 1).

The density of  $\beta_2$ - and  $\beta_1$ -adrenoceptors was assessed by competition binding utilizing the highly selective  $\beta_1$ -adrenoceptor antagonist CGP20712A (Fig. 2). These experiments demonstrated that of the total  $\beta$ -adrenoceptors, 91 $\pm$ 10% were  $\beta_2$ -adrenoceptors (n=88).

#### 3.2. $\beta$ -adrenoceptor expression in different zones of human lung

The samples used in these studies were sub-pleural and taken from the periphery of either upper, middle or lower zones of lung following lobectomies. In order to determine whether the variability in  $\beta$ -adrenoceptor density and subtype distribution was due to the area of lung being sampled, binding assays were performed on tissue sampled from the periphery of upper, middle and lower zones, as well as deep, central regions of lung, following pneumonectomies (Table 2). There was no difference, statistically ( $P > 0.05$ ), among regions of lung in the density (fmol/mg protein) of (a) total  $\beta$ -adrenoceptors, (b)  $\beta_2$ -adrenoceptors, or (c)  $\beta_1$ -adrenoceptors.

#### 3.3. Influence of SNPs on $\beta_2$ -adrenoceptor expression

In order to establish whether polymorphisms within *ADRB2* influence receptor expression in human lung, the 88 lung preparations whose  $\beta_2$ -adrenoceptor densities had been determined (see section 3.1.), were genotyped at 5 positions of *ADRB2* (-367, -47, 46, 79 and 491) known to be polymorphic. For these positions, the frequency of the less prominent allele was either 0.40 or 0.41 with the exception of nucleotide position 491 in which only 5 heterozygotes and no homozygotes of the less frequent allele were detected (Table 3).

Position -47, within the promoter region, has been reported to influence  $\beta_2$ -adrenoceptor expression [11]. However, our data demonstrate that there was no influence ( $P > 0.05$ ) of position -47 on  $\beta_2$ -adrenoceptor expression in the 88 lung preparations that were studied (Fig. 3). Position -367 within the promoter region of *ADRB2* has also been linked to influencing receptor expression [12,15]. However, in human lung this position had no influence on  $\beta_2$ -adrenoceptor expression (Table 4).

The potential influence of coding block SNPs on  $\beta_2$ -adrenoceptor expression in lung was evaluated (Table 4). None of the positions had an influence with the exception of position 491 (amino acid position 164) in which preparations genotyped as heterozygous expressed significantly ( $P = 0.0005$ ) higher levels of  $\beta_2$ -adrenoceptor than homozygotes (Fig. 4).

#### 4. Discussion

$\beta_2$ -adrenoceptor agonists continue to be significantly important drugs used to manage asthma [5]. Therapeutically,  $\beta_2$ -adrenoceptor agonists act as bronchodilators but additional benefits may include the stabilization of inflammatory cell activity [7,8]. As agonists that mediate effects through pulmonary  $\beta_2$ -adrenoceptors, the actions of these drugs are likely to be influenced by the extent of  $\beta_2$ -adrenoceptor expression in the lung. In the present study, we found vast differences, as much as ten-fold, in the extent of  $\beta$ -adrenoceptor expression among lung tissue specimens. Our intention was to determine whether this wide difference in the degree of receptor expression might be genetically influenced.

Polymorphisms within the promoter region of *ADRB2*, especially those at –47T>C (BUP-cys to BUP-arg) and –367T>C, have been associated with differences in  $\beta_2$ -adrenoceptor expression in transfected cells [11-15]. By contrast, a study using lymphocytes isolated from asthmatics demonstrated that there was no association between the polymorphism at –47 and  $\beta_2$ -adrenoceptor expression [17]. While lymphocytes were used in this study as a representation of lung  $\beta_2$ -adrenoceptors, it is known that the behaviour and expression of  $\beta_2$ -adrenoceptors can be influenced by the tissue or cell in which the receptor is expressed [25-27]. Nevertheless, findings from the present study are in accord with those reported for lymphocytes since there was no influence of position –47 on  $\beta_2$ -adrenoceptor expression in human lung. Indeed, neither of the SNPs (–47 and –367) found up-stream from the coding block and that, conceivably, could have an influence on  $\beta_2$ -adrenoceptor expression were associated with differences in receptor density in this study.

A potential influence of SNPs within the coding block of *ADRB2* was also considered. Thus, polymorphisms at positions 46 and 79, corresponding with amino acid positions 16 and 27 of the  $\beta_2$ -adrenoceptor, were examined to establish whether any link existed with receptor expression. Positions 16 and 27 have been associated with differences in the degree of  $\beta_2$ -adrenoceptor down-regulation [28,29] such that expression of a particular genotype at either of these two positions could, potentially, impact on the degree of receptor expression in lung. However, in the present study, there was no influence of either of these two positions on  $\beta_2$ -adrenoceptor expression.

In addition, we also considered an alternative polymorphism, 491C>T, within the coding block corresponding with a change in amino acid at position 164 of the  $\beta_2$ -adrenoceptor from thr to ile [30]. In keeping with a number of studies [24,30-32], the appearance of the less common allele was very infrequent with only 5 preparations out of 88 genotyped as heterozygous at this position with none homozygous for the less common allele. Lung preparations genotyped as thr164ile expressed significantly greater levels, almost twice as many,  $\beta_2$ -adrenoceptors as those genotyped as thr164thr. While interesting, these data were unexpected since no precedents exist in the literature for such an outcome. One possible explanation for the markedly greater  $\beta_2$ -adrenoceptor density in lungs genotyped as thr164ile could be due to a compensatory mechanism. In transfected cells, agonists bind to the ile164-expressing  $\beta_2$ -adrenoceptor with lower affinity and the receptor couples less efficiently to G-protein compared to the thr164-expressing  $\beta_2$ -adrenoceptor [33]. This could mean that diminished constitutive or promoted down-regulation occurs of the ile164-expressing  $\beta_2$ -adrenoceptor due to impaired activation of the protein kinases (protein kinase A and G-protein receptor

kinase) that are thought to be involved in receptor desensitization [34-36]. Consequently, this could result in a relative increase in  $\beta_2$ -adrenoceptors in preparations expressing the less frequent allele at position 164. While such a scheme is, admittedly, speculative, depressed desensitization of the ile164-expressing  $\beta_2$ -adrenoceptor in transfected cells has been reported [33].

Overall, these findings indicate that common polymorphisms in *ADRB2* do not influence  $\beta_2$ -adrenoceptor expression in human lung. This suggests that a direct genetic influence is not responsible for the wide variability in  $\beta_2$ -adrenoceptor density observed and that alternative influences contribute to the variability. We explored the possibility that the underlying lung pathophysiology might influence  $\beta_2$ -adrenoceptor expression by blinded histological review of the samples taken. Microscopic analysis of different lung tissue samples known to express a range of  $\beta_2$ -adrenoceptor densities, was performed by a single observer (SKS). The analysis indicated minimal differences among samples in oedema, inflammatory cell infiltration, fibrosis and emphysema (see Fig. 5). These minimal differences are often seen in background resected lung tissues and are judged unlikely to have any material impact on  $\beta$ -adrenoceptor density.

One alternative factor that could potentially influence  $\beta_2$ -adrenoceptor expression in lung is prior exposure to medications, in particular, to  $\beta_2$ -agonists and corticosteroids. Exposure to  $\beta_2$ -agonists could lead to  $\beta_2$ -adrenoceptor down-regulation [18,34-37] and corticosteroids have been shown to increase  $\beta_2$ -adrenoceptor expression in a variety of test systems [38-41]. In the present study, tissue was donated anonymously and drug histories were, therefore, unavailable. However, in an unrelated study in which 250 individuals had donated lung tissue for study and for whom details exist, 2% were on



corticosteroids, 5% were on  $\beta_2$ -agonists and 4% were on a combination of corticosteroids and  $\beta_2$ -agonists. If an assumption is made that a similar proportion of the present study population was exposed to these drugs, it seems unlikely that exposure to corticosteroids and  $\beta_2$ -agonists is a substantially confounding influence. Indeed, whether prior exposure to  $\beta_2$ -agonists has a substantial effect on receptor density in the lung is a moot point since reports have shown that the pulmonary  $\beta_2$ -adrenoceptor is unusually resistant to down-regulation [25,26,42]

In summary, the present study has shown that common polymorphisms both within the promoter region and the coding block of *ADRB2* do not influence the expression of  $\beta_2$ -adrenoceptors in human lung. By contrast, there was an association between the rare polymorphism at position 491 (amino acid 164) and  $\beta_2$ -adrenoceptor expression. However, the possibility that other, recently identified SNPs in *ADRB2*, 5' and 3' of the region studied [2], might influence receptor expression cannot be excluded.

In conclusion, these findings indicate that common polymorphisms in *ADRB2* do not influence  $\beta_2$ -adrenoceptor expression in human lung. This suggests that a direct genetic influence is not responsible for the wide variability in  $\beta_2$ -adrenoceptor density observed and that alternative influences contribute to the variability.

**Acknowledgements**

The authors are grateful to Mr J Edwards, Mr J Rao, Mr T Locke, Mr G Cooper and Mr D Hopkinson (Cardiothoracic Surgery), Dr SK Suvarna, Dr P Kitsanta and Dr C Layton (Histopathology) at the Northern General Hospital, Sheffield for their invaluable help in providing lung tissue specimens. The in-house sequencing facility and the assistance of Aileen McDermott, Helen Langsford and Dr Franco Di Giovine is gratefully acknowledged. This work was supported, in part, by Asthma UK.

ACCEPTED MANUSCRIPT

**References**

- [1] Brodde O-E, Leineweber K.  $\beta_2$ -adrenoceptor polymorphisms. *Pharmacogenetics* 2005;15:267-75.
- [2] Hawkins GA, Tantisira K, Meyers DA, Ampleford EJ, Moore WC, Klanderman B et al. Sequence, haplotype and association analysis of ADR $\beta_2$  in a multiethnic case-control study. *Am J Respir Crit Care Med* 2006;174:1101-9.
- [3] Green SA, Turki J, Hall IP, Liggett SB. Implications of genetic variability of human  $\beta_2$ -adrenergic receptor structure. *Pulmon Pharmacol* 1995;8:1-10.
- [4] Kirstein SI, Insel PA. Autonomic nervous system Pharmacogenomics: a progress report. *Pharmacol Rev* 2004;56:31-52.
- [5] Waldeck B.  $\beta$ -adrenoceptor agonists and asthma – 100 years of development. *Eur J Pharmacol* 2002;445:1-12.
- [6] Taylor DR, Kennedy MA. Beta-adrenergic receptor polymorphisms and drug responses in asthma. *Pharmacogenomics* 2002;3:173-84.
- [7] O'Connor BJ, Fuller RW, Barnes PJ. Non-bronchodilator effects of inhaled  $\beta_2$ -agonists. Greater protection against adenosine monophosphate- than methacholine-induced bronchoconstriction in asthma. *Am J Respir Crit Care Med* 1994;150:381-7.
- [8] Nightingale JA, Rogers DF, Barnes PJ. Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. *Am J Respir Crit Care Med* 1999;159:1786-90.
- [9] MacEwan DJ, Kim GD, Milligan G. Analysis of the role of receptor number in defining the intrinsic activity and potency of partial agonists in neuroblastoma x

glioma hybrid NG108-15 cells transfected to express differing levels of the human  $\beta_2$ -adrenoceptor. *Mol Pharmacol* 1995;48:316-25.

- [10] Taylor DA, Jensen MW, Aikman SL, Harris JG, Barnes PJ, O'Connor BJ. Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. *Am J Respir Crit Care Med* 1997;156:1731-7.
- [11] McGraw DW, Forbes SL, Kramer LA, Liggett SB (1998). Polymorphisms of the 5' leader cistron of the human  $\beta_2$ -adrenergic receptor regulate receptor expression. *J Clin Invest* 1998;102:1927-32.
- [12] Scott MGH, Swan C, Wheatley AP, Hall IP. Identification of novel polymorphisms within the promoter region of the human  $\beta_2$ -adrenergic receptor gene. *Br J Pharmacol* 1999;126:841-4.
- [13] Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K et al. Complex promoter and coding region  $\beta_2$ -adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. *Proc Natl Acad Sci* 2000;97:10483-8.
- [14] Johnatty SE, Abdellatif M, Shimmin L, Clark, RB, Boerwinkle E.  $\beta_2$ -adrenergic receptor 5' haplotypes influence promoter activity. *Br J Pharmacol* 2002;137:1213-6.
- [15] Westland R, van Veen A, Jansen HM, Jonkers RE, Wierenga EA (2004). Limited impact of multiple 5' single-nucleotide polymorphisms on the transcriptional control of the human  $\beta_2$ -adrenoceptor gene. *Immunogenetics* 2004;56:625-30.

- [16] Parola AL, Kobilka BK. The peptide product of a 5' leader cistron in the  $\beta_2$  adrenergic receptor mRNA inhibits receptor synthesis. *J Biol Chem* 1994;269:4497-505.
- [17] Lipworth B, Koppelman GH, Wheatley AP, Le Jeune I, Coutie W, Meurs H et al.  $\beta_2$  adrenoceptor polymorphisms: extended haplotypes and functional effects in peripheral blood mononuclear cells. *Thorax* 2002;57:61-6.
- [18] Nishikawa M, Mak JCW, Barnes PJ. Effect of short- and long-acting  $\beta_2$ -adrenoceptor agonists on pulmonary  $\beta_2$ -adrenoceptor expression in human lung. *Eur J Pharmacol* 1996;318:123-9.
- [19] Chong LK, Chess-Williams R, Peachell PT. Pharmacological characterisation of the  $\beta$ -adrenoceptor expressed by human lung mast cells. *Eur J Pharmacol* 2002;437:1-7.
- [20] Dooley DJ, Bittiger H, Reymann NC. CGP20712A: a useful tool for quantitating  $\beta_1$ - and  $\beta_2$ -adrenoceptors. *Eur J Pharmacol* 1986;130:137-9.
- [21] Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem* 1951;193:265-75.
- [22] Graham DE (1978). The isolation of high molecular weight DNA from whole organisms or large tissue masses. *Anal Biochem* 1978;85:604-13.
- [23] Chong LK, Chowdry J, Ghahramani P, Peachell PT. Influence of genetic polymorphisms in the  $\beta_2$ -adrenoceptor on desensitization in human lung mast cells. *Pharmacogenetics* 2000;10:153-62.
- [24] Aynacioglu AS, Cascorbi I, GÜngör K, Özkur M, Bekir N, Roots I et al. Population frequency, mutation linkage and analytical methodology for the Arg16Gly, Gln27Glu

- and Thr164Ile polymorphisms in the  $\beta_2$ -adrenergic receptor among Turks. *Br J Clin Pharmacol* 1999;48:761-4.
- [25] Hasegawa M, Townley RG. Difference between lung and spleen susceptibility of beta-adrenergic receptors to desensitization by terbutaline. *J Allergy Clin Immunol* 1983;71:230-8.
- [26] Hauck RW, Bohm M, Gegenbach S, Sunder-Plassmann L, Fruhmann G et al.  $\beta_2$ -adrenoceptors in human lung and peripheral mononuclear leukocytes of untreated and terbutaline-treated patients. *Chest* 1990;98:376-81.
- [27] Chong LK, Peachell PT.  $\beta$ -adrenoceptor reserve in human lung: a comparison between airway smooth muscle and mast cells. *Eur J Pharmacol* 1999;378: 115-22.
- [28] Green SA, Turki J, Bejarano P, Hall IP, Liggett SB. Influence of  $\beta_2$ -adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. *Am J Respir Cell Mol Biol* 1995;13:25-33.
- [29] Green SA, Turki J, Innis M, Liggett SB (1994). Amino-terminal polymorphisms of the human  $\beta_2$ -adrenergic receptor impart distinct agonist-promoted regulatory properties. *Biochemistry* 1994;33:9414-9.
- [30] Reihnsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the  $\beta_2$ -adrenergic receptor in normal and asthmatic subjects. *Am J Respir Cell Mol Biol* 1993;8:334-9.
- [31] Büscher R, Eilmes KJ, Grasemann H, Torres B, Knauer N, Insel PA, Ratjen F.  $\beta_2$ -adrenoceptor gene polymorphisms in cystic fibrosis lung disease. *Pharmacogenetics* 2002;12:347-53.

- [32] Hall IP, Blakey JD, Al Balushi KA, Wheatley A, Sayers I, Pembrey ME et al.  $\beta_2$ -adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. *Lancet* 2006;368:771-9.
- [33] Green, SA, Cole G, Jacinto M, Innis M, Liggett SB. A polymorphism of the human  $\beta_2$ -adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. *J Biol Chem* 1993;268:23116-21.
- [34] Benovic JL, Staniszewski C, Mayor F, Caron MG, Lefkowitz RJ.  $\beta$ -adrenergic kinase. Activity of partial agonists for stimulation of adenylate cyclase correlates with ability to promote receptor phosphorylation. *J Biol Chem* 1988;263:3893-7.
- [35] January B, Seibold A, Whaley B, Hipkin RW, Lin D, Schonbrunn A et al.  $\beta$ -Adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists. *J Biol Chem* 1997;272:23871-9.
- [36] Kohout TA, Lefkowitz RJ. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. *Mol Pharmacol* 2003;63:9-18.
- [37] Ferguson SSG. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. *Pharmacol Rev* 2001;53:1-24.
- [38] Lai E, Rosen OM, Rubin CS. Dexamethasone regulates the  $\beta$ -adrenergic receptor subtype expressed by 3T3-L1 pre-adipocytes and adipocytes. *J Biol Chem* 1982;257:6691-6.
- [39] Collins S, Caron MG, Lefkowitz RJ.  $\beta_2$ -adrenergic receptors in hamster smooth muscle cells are transcriptionally regulated by glucocorticoids. *J Biol Chem* 1988;263: 9067-70.

- [40] Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids increase  $\beta_2$ -adrenergic receptor transcription in human lung. *Am J Physiol* 1995;268:L41-L46.
- [41] Baraniuk JN, Ali M, Brody D, Maniscalco J, Gaumond E, Fitzgerald T et al. Glucocorticoids induce  $\beta_2$ -adrenergic receptor function in human nasal mucosa. *Am J Respir Crit Care Med* 1997;155:704-10.
- [42] Bai TR, Mak JCW, Barnes PJ. A comparison of  $\beta$ -adrenergic receptors and in vitro relaxant responses to isoproterenol in asthmatic airway smooth muscle. *Am J Respir Cell Mol Biol* 1992;6:647-51.



**Table 1** Primers used to amplify regions of *ADRB2* by PCR

<i>Primer pair</i>	<i>Primers</i>	<i>Annealing conditions</i>	<i>Fragment size (bp)</i>
1	5'-CTCCAAGCCAGCGTGTGTTT-3' (sense) 5'-GTGCACAGGACTTTAGGGGA-3' (antisense)	60°C, 45 s	627
2	5'-CATAACGGGCAGAACGCACTG-3' (sense) 5'-CACAATCCACACCATCAGAAT-3' (antisense)	56°C, 45 s	716
3	5'-GTGATCGCAGTGGATCGCTACT-3' (sense) 5'-AGACGAAGACCATGATCCAG-3' (antisense)	58°C, 45 s	280

**Table 2**  $\beta$ -adrenoceptor density in different zones of human lung

	<i>Zones</i>			
	<i>Upper</i>	<i>Middle</i>	<i>Lower</i>	<i>Central</i>
$\beta$ -AR density (fmol/mg protein)	80 $\pm$ 13	90 $\pm$ 16	75 $\pm$ 10	114 $\pm$ 18
$\beta_2$ -AR (%)	92 $\pm$ 1	95 $\pm$ 4	95 $\pm$ 2	94 $\pm$ 2
$K_D$ (nM)	0.05 $\pm$ 0.01	0.04 $\pm$ 0.01	0.04 $\pm$ 0.01	0.05 $\pm$ 0.01

Tissue was sampled from peripheral regions of upper, middle and lower zones and from deep, central zones of lung following pneumonectomies. Membranes were prepared from these samples and  $\beta$ -adrenoceptor ( $\beta$ -AR) density was determined by saturation binding assays using the radioligand [ $^{125}$ I]-cyanopindolol (0.01563 – 2 nM). The  $K_D$  values for [ $^{125}$ I]-cyanopindolol, determined in different zones of lung, are provided in the table and were not significantly different, statistically ( $P > 0.05$ ), from each other.

Discrimination of  $\beta_2$ - and  $\beta_1$ -adrenoceptors was determined by competition of the radioligand with CGP20712A. There was no difference, statistically ( $P > 0.05$ ), among zones of lung in the density (fmol/mg protein) of (a) total  $\beta$ -adrenoceptors, (b)  $\beta_2$ -adrenoceptors, or (c)  $\beta_1$ -adrenoceptors. Values are means $\pm$ S.E.M. for seven experiments.

**Table 3** Allelic frequencies of polymorphic positions in *ADRB2* (n=88)

<i>Position (aa)</i>	<i>SNP</i>	<i>amino acid</i>	<i>frequency</i>
-367	T	-	0.59
	C	-	0.41
-47	T	cys	0.60
	C	arg	0.40
46 (16)	G	gly	0.60
	A	arg	0.40
79 (27)	C	gln	0.59
	G	glu	0.41
491 (164)	C	thr	0.97
	T	ile	0.03

Each polymorphic position was in Hardy-Weinberg equilibrium.

**Table 4** Influence of SNPs on  $\beta_2$ -adrenoceptor expression in human lung

<i>Genotype</i>	<i><math>\beta_2</math>-adrenoceptor density (fmol/mg protein)</i>				
	<i>-367</i>	<i>-47</i>	<i>46</i>	<i>79</i>	<i>491</i>
0	65±6	71±6	71±6	67±6	69±4
1	84±6	77±6	74±6	79±6	126±15*
2	63±6	61±6	71±8	63±6	-

For each polymorphic position, homozygotes for the more common allele are represented by set 0 and for the less common allele by set 2 and for heterozygotes by set 1. Further information concerning alleles and allele frequencies can be found in table 3. None of the polymorphisms influenced  $\beta_2$ -adrenoceptor expression except position 491 (amino acid 164) in which preparations that were heterozygous (n=5) at this position expressed significantly (\* $P = 0.0005$ ) higher levels of receptor than homozygotes (n=83).

### Figure legends

**Figure 1** Saturation binding curves of the radioligand [ $^{125}$ I]-cyanopindolol to human lung membranes. Specific binding was determined by evaluating binding of the radioligand to membranes in the absence and presence of the  $\beta$ -adrenoceptor antagonist, propranolol (1  $\mu$ M). Saturation curves were determined by non-linear regression analysis. Representative data for three lung preparations are shown for which receptor densities ( $B_{\max}$ ) were 110, 87 and 46 fmol/mg protein and  $K_D$  values for [ $^{125}$ I]-cyanopindolol were 0.06, 0.05 and 0.02 nM (squares, circles and triangles, respectively).

**Figure 2** Distribution of  $\beta$ -adrenoceptor subtypes in human lung. Membranes were prepared from lung samples (n=88) and discrimination of  $\beta_2$ - and  $\beta_1$ -adrenoceptors was determined by competition of the radioligand [ $^{125}$ I]-cyanopindolol (0.0625 nM) with increasing concentrations of the highly  $\beta_1$ -adrenoceptor-selective antagonist, CGP20712A. The figure shows representative data in which each panel depicts competition binding for an individual preparation. CGP20712A displayed both a high ( $11.0 \pm 0.5$ ) and lower ( $5.6 \pm 0.1$ )  $pK_i$  associated with interactions at  $\beta_1$ - and  $\beta_2$ -adrenoceptors, respectively. The percentage of  $\beta_1$ -adrenoceptors in these preparations ranged from 14 to 21%.

**Figure 3** Influence of position -47T>C on  $\beta_2$ -adrenoceptor expression in human lung. Polymorphisms at -47 lead to changes in the terminal amino acid (cys to arg) of a putative 19 amino acid peptide, BUP, that has been linked to  $\beta_2$ -adrenoceptor expression.

There was no difference ( $P = 0.35$ ) in the expression of  $\beta_2$ -adrenoceptors in human lung genotyped as BUP-cys ( $71 \pm 6$  fmol/mg protein;  $n=34$ ), BUP-cys/arg ( $77 \pm 6$  fmol/mg protein;  $n=38$ ) or BUP-arg ( $61 \pm 6$  fmol/mg protein;  $n=16$ ). Horizontal bars show mean values.

**Figure 4** Influence of position 491C>T on  $\beta_2$ -adrenoceptor expression in human lung. Polymorphisms at 491 lead to changes (thr to ile) in the amino acid at position 164. The expression of  $\beta_2$ -adrenoceptors in human lung was significantly ( $P = 0.0005$ ) higher in preparations genotyped as heterozygous (thr/ile;  $126 \pm 15$  fmol/mg protein;  $n=5$ ) compared to homozygous preparations (thr;  $69 \pm 4$  fmol/mg protein;  $n=83$ ). Horizontal bars show mean values. In order to confirm these data, the 5 preparations, heterozygous at position 491, were reassessed for  $\beta_2$ -adrenoceptor density. Following reassessment, mean  $\beta_2$ -adrenoceptor density determinations were similar ( $125 \pm 26$  fmol/mg protein) and were significantly ( $P = 0.006$ ) different from densities seen in homozygous preparations.

**Figure 5** Human lung histology. Twelve human lung preparations known to express high, low and intermediary levels of  $\beta_2$ -adrenoceptor were examined histologically. Sections of lung tissue were fixed in buffered formalin and prepared through paraffin embedding for analysis. The samples were scored for oedema, fibrosis, emphysema, acute and chronic inflammation, blood vessel and airway integrity. This analysis was performed blind by a single observer (SKS). Although there were slight morphological differences among the 12 lungs studied, these were judged non-significant regarding any inflammation component. The two representative sections shown are lung preparations

expressing  $\beta_2$ -adrenoceptor densities of (a) 29 fmol/mg protein and (b) 171 fmol/mg protein. (a) Photomicrograph of lung 551, showing slight interstitial fibrosis (F) and mucus inspissation (M) in the lung. A very minor interstitial accumulation of chronic inflammatory cells was noted without accumulation or frank suppuration. Minimal airspace dilatation was seen, (A). (b) Photomicrograph of lung 516, showing alveolated lung with some emphysematous changes (variable airspace dilatation, (A)) and only very minor interstitial expansion (F). A prominent blood vessel (BV) is noted and there is some minor soot black pigment noted. Again, a very mild chronic inflammatory cell population was seen in the interstitium (x 200, Haematoxylin & Eosin).




figure 1

ACCEPTED MANUSCRIPT






figure 2

ACCEPTED 1




figure 3

amino acid at BUP19

ACCEPTED MANUSCRIPT




figure 4

amino acid at 164

ACCEPTED MANUSCRIPT




Figure 5a

ACCEPTED




Figure 5b

ACCEPTED